Your browser doesn't support javascript.
loading
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Jeyakumar, A; Chalas, E; Hindenburg, A.
Affiliation
  • Jeyakumar A; Oncology/Hematology Division, Department of Medicine, Winthrop University Hospital, Mineola, New York 11501, USA. alwinj@excite.com
Gynecol Oncol ; 82(3): 578-80, 2001 Sep.
Article in En | MEDLINE | ID: mdl-11520160
ABSTRACT

BACKGROUND:

Yolk sac tumors of the ovary are generally very responsive to chemotherapy; however, they are difficult to manage in the setting of platinum resistance where treatment options are limited and outcomes are poorer. CASE We present a 39-year-old woman who had a platinum-resistant yolk sac ovarian tumor. She achieved complete remission on an innovative regimen of docetaxel, gemcitabine, and thalidomide.

CONCLUSION:

The combination of docetaxel, gemcitabine, and thalidomide might be an active regimen for platinum-resistant ovarian nondysgerminomas and further investigation of this combination is warranted.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Endodermal Sinus Tumor / Taxoids Limits: Adult / Female / Humans Language: En Journal: Gynecol Oncol Year: 2001 Document type: Article Affiliation country: Estados Unidos
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Endodermal Sinus Tumor / Taxoids Limits: Adult / Female / Humans Language: En Journal: Gynecol Oncol Year: 2001 Document type: Article Affiliation country: Estados Unidos